Improving the therapeutic window of anti-CTLA-4 mAbs. Ipilimumab (Ipi), an antagonist anti-CTLA-4 IgG1 mAb, was the first antibody immune checkpoint inhibitor (CPI), first approved by the FDA in 2011 for the treatment of melanoma [22]. The gene discussed is CTLA4; the disease is melanoma.